Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 16 Feb 2023
As more states repeal or restrict abortion laws, the number of patients, the number of workers needed, and the cost of heart disease will increase. How should hospitals and policy makers prepare?
Read Full NewsFindings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.
Here's some of what is coming soon to NeurologyLive® this week.
Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.
FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.
5 Pulmonology Headlines You Missed in November 2025
Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43
Stage 5 CKD May Reverse Female Survival Advantage
1.
Dissociative identity disorder: method or fact?
2.
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement
3.
AI tool automates liver tumor detection and monitoring
4.
Insurance Claim Denials for Preventive Care More Common in At-Risk Patients
5.
Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC
1.
Everything You Need to Know About RDW-CV: A Comprehensive Guide
2.
Advancing Cancer Trials: Integrating Master Protocols and Immunotherapy Guidelines
3.
Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications
4.
Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact
5.
Understanding Abemaciclib: A Breakthrough Treatment for Breast Cancer
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
3.
Navigating the Complexities of Ph Negative ALL - Part V
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
5.
Navigating the Complexities of Ph Negative ALL - Part XV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge